(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.

@article{Lalezari1995S13hydroxy2phosphonylmethoxypropy,
  title={(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.},
  author={Jacob P. Lalezari and William Lawrence Drew and Eileen Glutzer and Cindy James and Diane Miner and John Flaherty and Peter E. Fisher and Kenneth C. Cundy and James T Hannigan and John C. Martin},
  journal={The Journal of infectious diseases},
  year={1995},
  volume={171 4},
  pages={788-96}
}
Cidofovir, (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, is a novel antiviral nucleotide analogue with potent in vitro and in vivo activity against cytomegalovirus (CMV) and other herpesviruses. Thirty-one human immunodeficiency virus-seropositive patients with asymptomatic CMV excretion were evaluated in a phase I/II study with 2 regimens of cidofovir: cidofovir alone at doses of 0.5, 1.0, 3.0, or 10.0 mg/kg/week (20 patients) and cidofovir at 3.0, 5.0, or 7.5 mg/kg with concomitant… CONTINUE READING